Inferior vena cava filters: What radiologists need to know

Harvey, John Julian; Hopkins, Jonathan; McCafferty, Ian; Jones, R.

doi:10.1016/j.crad.2013.01.001

Cited by 40 publications

(33 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La trombosis venosa en extremidades inferiores y pelvis es una patología muy frecuente y su complicación más temida, la embolia pulmonar (EP) (alrededor de 150.000 a 300.000 casos anuales en Estados Unidos de Norteamérica (USA)) puede presentarse como muerte súbita en 25 a 40% de los pacientes afectados 7 . El tratamiento para prevenir la EP es la anticoagulación con heparina y drogas orales, sin embargo, hay ocasiones en que este tratamiento no puede implementarse por existir contraindicaciones o ser inefectivo.…”

Section: Discussionunclassified

“…Se consideran como indicaciones absolutas para la colocación de filtros el tromboembolismo venoso recurrente a pesar de anticoagulación adecuada, la incapacidad de mantener una anticoagulación en niveles terapéuticos, la contraindicación de utilizar anticoagulantes (alergias, cirugía mayor) y las complicaciones hemorrágicas. Existen también indicaciones relativas y profilácticas 7,9,12 . En este paciente, la indicación del filtro en VCI fue una EP después de cirugía ocular en que no era recomendable utilizar anticoagulación en el postoperatorio.…”

Section: Discussionunclassified

“…La ubicación habitual en que se instalan los filtros es en la VCI infrarenal, para no interferir en el drenaje de las venas renales. Sin embargo, hay ocasiones en que ello no es posible o recomendable y deben ponerse en posición suprarrenal como ocurre cuando hay duplicación de la VCI, como sucedió en este paciente 7 . Esta ubicación es tan segura como la infrarenal 17 .…”

Section: Discussionunclassified

See 2 more Smart Citations

Trombosis bilateral de venas renales e insuficiencia renal aguda secundaria a trombosis de un filtro en vena cava inferior

Vega

Díaz

2014

Rev. méd. Chile

View full text Add to dashboard Cite

Section: Discussionunclassified

See 1 more Smart Citation

Trombosis bilateral de venas renales e insuficiencia renal aguda secundaria a trombosis de un filtro en vena cava inferior

Vega

Díaz

2014

Rev. méd. Chile

View full text Add to dashboard Cite

“…Inferior vena cava filters are associated with high morbidity and can increase hypercoagulability; therefore, if placement is required, the filter should be removed as soon as possible (that is, once lmwh can be started). No available data support the addition of an ivc filter to pharmacologic anticoagulation therapy 52,65 . Conversely, patients with an ivc filter who can receive pharmacologic anticoagulation therapy should continue treatment as long as they are deemed at high risk of recurrent vte regardless of the presence or absence of a filter.…”

Section: 23mentioning

confidence: 99%

Evidence-Based Guidance on Venous Thromboembolism in Patients with Solid Tumours

Shea‐Budgell

Easaw

2014

Current Oncology

View full text Add to dashboard Cite

Venous thromboembolism (vte) is a serious, life-threatening complication of cancer. Anticoagulation therapy such as low molecular weight heparin (lmwh) has been shown to treat and prevent vte. Cancer therapy is often complex and ongoing, making the management of vte less straightforward in patients with cancer. There are no published Canadian guidelines available to suggest appropriate strategies for the management of vte in patients with solid tumours. We therefore aimed to develop a clear, evidence-based guideline on this topic. A systematic review of clinical trials and meta-analyses published between 2002 and 2013 in PubMed was conducted. Reference lists were handsearched for additional publications. The National Guidelines Clearinghouse was searched for relevant guidelines. Recommendations were developed based on the best available evidence. In patients with solid tumours, lmwh is recommended for those with established vte and for those without established vte but with a high risk for developing vte. Options for lmwh include dalteparin, enoxaparin, and tinzaparin. No one agent can be recommended over another, but in the setting of renal insufficiency, tinzaparin is preferred. Unfractionated heparin can be used under select circumstances only (that is, when rapid clearance of the anticoagulant is desired). The most common adverse event is bleeding, but major events are rare, and with appropriate follow-up care, bleeding can be monitored and appropriately managed.

show abstract

“…The primary indication for insertion of an inferior vena cava (ivc) filter is the presence of acute dvt with a concurrent contraindication to anticoagulation [44][45][46][47] . The addition of an ivc filter to antithrombotic therapy is generally not recommended.…”

Section: Inferior Vena Cava Filtermentioning

confidence: 99%

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment

Easaw¹,

Shea‐Budgell²,

Wu³

et al. 2015

Curr. Oncol.

View full text Add to dashboard Cite

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation therapy is used to treat vte; however, patients with cancer have unique clinical circumstances that can often make decisions surrounding the administration of therapeutic anticoagulation complicated. No national Canadian guidelines on the management of established cancer-associated thrombosis have been published. We therefore aimed to develop a consensus-based, evidence-informed guideline on the topic.PubMed was searched for clinical trials and meta-analyses published between 2002 and 2013. Reference lists of key articles were hand-searched for additional publications. Content experts from across Canada were assembled to review the evidence and make recommendations.Low molecular weight heparin is the treatment of choice for cancer patients with established vte. Direct oral anticoagulants are not recommended for the treatment of vte at this time. Specific clinical scenarios, including the presence of an indwelling venous catheter, renal insufficiency, and thrombocytopenia, warrant modifications in the therapeutic administration of anticoagulation therapy. Patients with recurrent vte should receive extended (>3 months) anticoagulant therapy. Incidental vte should generally be treated in the same manner as symptomatic vte. There is no evidence to support the monitoring of anti–factor Xa levels in clinically stable cancer patients receiving prophylactic anticoagulation; however, levels of anti–factor Xa could be checked at baseline and periodically thereafter in patients with renal insufficiency. Follow-up and education about the signs and symptoms of vte are important components of ongoing patient care.

show abstract

Inferior vena cava filters: What radiologists need to know

Cited by 40 publications

References 62 publications

Trombosis bilateral de venas renales e insuficiencia renal aguda secundaria a trombosis de un filtro en vena cava inferior

Trombosis bilateral de venas renales e insuficiencia renal aguda secundaria a trombosis de un filtro en vena cava inferior

Evidence-Based Guidance on Venous Thromboembolism in Patients with Solid Tumours

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment

Contact Info

Product

Resources

About